Published in Ecancermedicalscience on February 06, 2008
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996) 6.18
Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med (1991) 3.53
Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med (1996) 3.35
Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med (1993) 2.80
Menopause and coronary heart disease. The Framingham Study. Ann Intern Med (1978) 2.62
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation (2004) 1.72
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med (2001) 1.54
Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet (1999) 1.48
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J (1998) 1.26
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol (1997) 1.21
Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med (1997) 1.07
Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol (1999) 1.04
Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol (2001) 0.99
Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey. Thromb Haemost (2001) 0.98
The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis (1998) 0.96
Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost (1992) 0.96
A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res (2004) 0.92
Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res (1996) 0.91
Multiple beneficial effects of estrogen on lipoprotein metabolism. J Clin Endocrinol Metab (1997) 0.90
Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J (1997) 0.89
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol (2003) 0.86
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril (2001) 0.85
Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis (2003) 0.85
Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat (1999) 0.83
Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial. Int J Cardiol (2003) 0.82
Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). Eur J Clin Nutr (2005) 0.82
Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett (1996) 0.82
Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation (2003) 0.80
A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab (2003) 0.80
Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol (2004) 0.80
The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2001) 0.79
Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest (2002) 0.79
Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines. Tumour Biol (1997) 0.79
Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. J Thromb Haemost (2003) 0.78
Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. J Cardiovasc Pharmacol (2006) 0.78
Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud (1993) 0.78
Effects of estrogen replacement therapy on thrombin generation. Thromb Res (1997) 0.77
The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol (1997) 0.77
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature (2000) 4.10
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1995) 3.79
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 2.76
Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med (1991) 2.70
Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry (2010) 2.57
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg (2002) 2.41
Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg (1997) 2.21
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.09
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat (2009) 1.90
Age-period-cohort models: a comparative study of available methodologies. J Clin Epidemiol (1999) 1.90
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer (1990) 1.73
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol (2002) 1.73
Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J (2007) 1.71
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol (2007) 1.69
Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg (2005) 1.68
Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology (2011) 1.67
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 1.66
Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology (2008) 1.66
Rab4 affects both recycling and degradative endosomal trafficking. FEBS Lett (2001) 1.65
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer (1995) 1.60
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
Position sense acuity is diminished following repetitive low-intensity work to fatigue in a simulated occupational setting. Eur J Appl Physiol (2000) 1.57
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Estimation of the parenchymal-cell content of the parathyroid gland, using density-gradient columns. Preliminary report. Acta Pathol Microbiol Scand A (1977) 1.52
Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis. Antimicrob Agents Chemother (1984) 1.48
Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. J Cell Biol (2001) 1.46
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. J Clin Invest (2001) 1.45
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol (1994) 1.44
The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41
Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. Leukemia (2004) 1.39
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Malignant and benign human mammary disease: estrogen binding in relation to clinical data. Cancer (1974) 1.39
Post-surgical metabolic imbalance in adolescents with renal hypophosphatemic rickets. J Pediatr Endocrinol Metab (2000) 1.39
The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer (2001) 1.39
Normocalcemic hyperparathyroidism, kidney stones, and idiopathic hypercalciuria. Surgery (1975) 1.38
Tumour location and the effects of preoperative radiotherapy in the treatment of rectal cancer. Br J Surg (2001) 1.37
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int (2009) 1.36
The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) (1999) 1.34
Does nipple preservation in mastectomy improve satisfaction with cosmetic results, psychological adjustment, body image and sexuality? Breast Cancer Res Treat (2008) 1.33
The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int (2006) 1.31
Diabetes and breast cancer risk: a meta-analysis. Br J Cancer (2012) 1.30
Phosphate status affects the gene expression, protein content and enzymatic activity of UDP-glucose pyrophosphorylase in wild-type and pho mutants of Arabidopsis. Planta (2001) 1.29
The binding of estradiol-17beta to human breast cancers and other tissues in vitro. Cancer Res (1970) 1.27
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev (2001) 1.27
Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer (2006) 1.25
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Actions on gamma-motoneurones elicited by electrical stimulation of group I muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.24
The influence of group II muscle afferents and low threshold skin afferents on dynamic fusimotor neurones to the triceps surae of the cat. Brain Res (1977) 1.22
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer (2010) 1.21
Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol (1995) 1.21
Actions on gamma-motoneurones elicited by electrical stimulation of group III muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.20
Nuclear DNA-content of parathyroid cells in adenomas, hyperplastic and normal glands. Acta Pathol Microbiol Scand A (1977) 1.20
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS (2001) 1.19
Sucrose and light regulation of a cold-inducible UDP-glucose pyrophosphorylase gene via a hexokinase-independent and abscisic acid-insensitive pathway in Arabidopsis. Biochem J (2001) 1.18
The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci. Hum Immunol (1995) 1.18
Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int (2010) 1.18
VAMP3 null mice display normal constitutive, insulin- and exercise-regulated vesicle trafficking. Mol Cell Biol (2001) 1.18
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant (2012) 1.18
Localized muscle fatigue decreases the acuity of the movement sense in the human shoulder. Med Sci Sports Exerc (1999) 1.17
Actions on gamma-motoneurones elicited by electrical stimulation of group II muscle afferent fibres in the hind limb of the cat. J Physiol (1983) 1.17
A fatal case of pup infection with minute virus of canines (MVC). J Vet Diagn Invest (1996) 1.17
Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons. Implications for treatment? Knee Surg Sports Traumatol Arthrosc (2001) 1.16
Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res (1995) 1.15